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Rapid development of pulmonary
hypertension during treatment of
paediatric cancer
Manish Aggarwal, Laura Schuettpelz, Julie Kolodziej and R. Mark Grady
Department of Pediatrics, Washington University School of Medicine, Children’s Place, St Louis, MO, USA
Abstract
Paediatric pulmonary hypertension has been described as a secondary complication of
multiple diseases and their treatment. Limited information exists about the relationship
between pulmonary hypertension and cancer in children. A review of charts was performed
in all patients treated for cancer and developed pulmonary hypertension. A total of four
patients developed pulmonary hypertension during treatment of cancer. All patients had solid
tumors, had echocardiographic evidence of elevated right ventricular pressures, and required
intensive care stays. Treatment courses included inhaled and oral pulmonary vasodilators
along with systemic steroids. Each had normalisation of echocardiograms and resolution of
pulmonary symptoms. Prompt diagnosis of pulmonary hypertension and treatment with
pulmonary vasodilators and steroids are considered important measures followed by
chemotherapy and radiation regimens.
Paediatric pulmonary hypertension, once thought to be a rare condition, has been seem to
have increased prevalence in the last 10 years.1 This increase has been driven in part by a
larger number of children surviving with what were previously life-threatening conditions
such as CHD and chronic lung disease of prematurity.2,3 The incidence of pulmonary
hypertension among children with chronic lung disease of prematurity alone is as high as 40%.
The secondary diagnosis of pulmonary hypertension has also been noted in association with
other disorders as well.4,5 Despite recognition of the linkage between cancer and pulmonary
hypertension in adults and reporting of the pulmonary side effects from cancer and treatment
in children, little information exists on the association of pulmonary hypertension and cancer
in children.6,7 Here we report on a cohort of children whose cancer treatment was complicated
by pulmonary hypertension, emphasising the effectiveness of pulmonary hypertension therapy
and recoverability.
Methods
We retrospectively evaluated the clinical records of patients with evidence of elevated
pulmonary pressures and previously identified paediatric tumors. Patients with evidence of
significant left ventricular systolic dysfunction or large pulmonary thromboembolisms were
not analysed in this report. A total of four patients were found to have evidence of pulmonary
hypertension after a diagnosis of paediatric malignancy. We reviewed clinical history,
laboratory studies, echocardiograms, cardiac catheterisations, and CT scans. We tabulated
dosing of chemotherapeutic drugs and radiation to the chest. This retrospective review was
approved by the Human Research Protection Office at Washington University.
Results
Patient 1 was a 2-year-old former 24-week estimated gestational age female with history of
mild bronchopulmonary dysplasia but was currently at home without the need for respiratory
support. She presented to the emergency room with respiratory distress and seizures and was
found to have a nasopharyngeal mass. After excisional biopsy and additional imaging, she was
diagnosed with nasopharyngeal embryonal rhabdomyosarcoma with metastasis to multiple
skeletal sites. Her echocardiogram before chemotherapy showed normal biventricular function
with no signs of elevated pulmonary arterial pressures. She underwent chemotherapy that
included induction with vincristine, irinotecan, and steroids, with subsequent two rounds of
cyclophosphamide, doxorubicin, etoposide, ifosfamide, and vincristine. After 4 months and
her fifth round of chemotherapy, she was admitted to the ICU with fever and neutropenia and
signs of cardiogenic shock and cardiomegaly on a chest radiograph. An echocardiogram at this
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time revealed a dilated right ventricle with decreased function,
mild tricuspid regurgitation though insufficient to estimate right
ventricular pressure, and bowing of the interventricular septum
into the left ventricle, consistent with suprasystemic right ven-
tricular pressures. Her B-type natriuretic peptide was 5054 pg/ml
(normal 0–39 pg/ml). On initiation of inhaled nitric oxide,
milrinone, and epinephrine, clinical and echocardiographic
indicators improved within 24 hours. Upon weaning of inhaled
nitric oxide and inotropes, she again showed clinical and echo-
cardiographic signs of elevated pulmonary pressures. With re-
initiation of inhaled nitric oxide and starting a methylprednisone
burst, her echocardiogram again normalised. She was then started
on sildenafil and tolerated weaning of nitric oxide. She was sub-
sequently found to desaturate during the night and she was dis-
charged on nasal cannula oxygen and sildenafil and no further
evidence of pulmonary hypertension. She underwent additional
chemotherapy with vincristine and irinotecan as well as naso-
pharyngeal directed radiation with no worsening of echocardio-
grams. Though she was able to wean off the supplemental oxygen,
she had relapse of her cancer and passed away before attempted
wean of her sildenafil.
Patient 2 was a 3-month-old male who presented with an
enlarging head circumference found to have a pineal blastoma.
An initial attempt at surgical resection was aborted, owing to the
highly vascular nature of the tumour and subsequently developed
seizures with a small subdural haematoma. Initial echocardio-
gram showed normal ventricular function with no signs of ele-
vated right ventricular pressures. He was given inpatient
chemotherapy consisting of methotrexate, vincristine, etoposide,
cyclophosphamide, and cisplatin. During his hospitalisation,
which was complicated by hepatic dysfunction with hepatic
veno-occlusive disease and systemic hypertension treated with
amlodipine, he developed increased work of breathing and a
B-type natriuretic peptide of 1900 pg/ml and was admitted to the
ICU. A chest CT scan performed showed “ground glass opa-
cities.” At this time, an echocardiogram showed signs of systemic
right ventricular pressures including a dilated right ventricle with
decreased function, a flattened interventricular septum, and right
to left shunting across the patent foramen ovale confirmed by an
agitated saline contrast study. A study performed 1 month pre-
viously showed no signs of elevated right ventricular pressure. He
was started on inhaled nitric oxide through a high-flow nasal
cannula and intravenous milrinone. He appeared to improve on
inhaled nitric oxide over the next few days but developed
methemoglobinemia. Upon weaning off inhaled nitric oxide, he
developed worsening right ventricular dysfunction, flattened
interventricular septum, and an elevated tricuspid regurgitation
velocity suggesting systemic right ventricular pressures. At this
point, he was then started on sildenafil and a methylprednisone
burst with improvement. He was weaned off steroids and silde-
nafil over the subsequent month and never developed further
clinical or echocardiographic signs of pulmonary hypertension
despite additional chemotherapy of cisplatin and vincristine. He
had progression of his oncologic illness with subsequent death at
13 months of age.
Patient 3 was a 4-year-old male who presented with systemic
hypertension and found to have a large mass arising from his left
adrenal gland and encasing his left renal artery. He was diagnosed
with grade IV metastatic neuroblastoma with local extension and
metastasis to his spleen and bones. He was initiated on cyclo-
phosphamide and topotecan and then six rounds of chemother-
apy with cisplatin, etoposide, doxorubicin, and vincristine. His
multiple echocardiograms to this point showed no evidence of
right ventricular dysfunction or elevated pressures. He then
underwent an autologous stem cell transplant with subsequent
1 month of radiation therapy directed to the left infra-
diaphragmatic region (3600 centigray) with only a small por-
tion of the left lung receiving significant exposure. One week after
completion of radiation treatment, he presented to oncology
clinic with tachycardia, tachypnoea, and increased work of
breathing and was admitted to the ICU. He had a chest CT that
showed pulmonary oedema, bilateral pleural effusions, and car-
diomegaly without a pulmonary embolism or interstitial pneu-
monitis. Though only three months after a normal echocardiogram,
this study showed a large pericardial effusion, right atrial and
right ventricular dilatation with decreased function, bowing of the
ventricular septum causing “pancaking” of the left ventricle, giving
evidence of supra-systemic pulmonary hypertension. There was
also evidence formild left ventricular diastolic dysfunction on tissue
Doppler imaging. As he was in cardiogenic shock, he was started on
inhaled nitric oxide, epinephrine, milrinone, and aggressive
diuresis. His blood count revealed no signs of microangiopathic
haemolytic anaemia and was inconsistent with thrombotic micro-
angiopathy. He was also started on intravenous methylprednisone
for pulmonary hypertension. He had gradual improvement in his
examination and echocardiogram allowing inotropes and inhaled
nitric oxide to be discontinued. He subsequently was weaned off
steroids and remained ononly a small amount of diuretics. After the
clinical stabilisation, he was taken for a cardiac catheterisation
which showed mild pulmonary hypertension with a mean pul-
monary artery pressure of 26mmHg, indexed pulmonary vascular
resistance of 3.2Woods units ×m2, and pulmonary capillary wedge
pressures of 8mmHg. As his pulmonary pressures were nearly
normal during the catheterisation, no acute vasodilator testing was
performed. He continued to do well during the hospitalisation with
no additional signs of cardiovascular compromise and discharged
for outpatient treatment.
He was admitted to the ICU during treatment with dinutux-
imab and interleukin-2 administration because of concern for
fluid shifts associated with this medication and his recent history
of cardiovascular dysfunction. He had a normal baseline echo-
cardiogram and a Swan-Ganz catheter was placed. After 24 hours
of medication, he had fever, tachycardia, tachypnoea, and
increased mean pulmonary artery pressure up to 54mmHg,
pulmonary wedge pressures of 9mmHg, and indexed pulmonary
vascular resistance of 14.0Woods units ×m2. A repeat echo-
cardiogram showed no pericardial effusion, but increased tricus-
pid regurgitation with an elevated TR jet, and normal right
ventricular function. He had no improvement with nasal cannula
oxygen but saw immediate improvement on initiation of inhaled
nitric oxide to mean pulmonary artery pressure of 40mmHg,
pulmonary wedge pressure of 8mmHg, and indexed pulmonary
vascular resistance of 5.5Woods units ×m2. These further nor-
malised over the next 12 hours. He was started on sildenafil after
the completion of the chemotherapeutics to minimise effects of
pulmonary hypertension during subsequent chemotherapy. Sub-
sequent rounds of treatment with dinutuximab and interleukin-2
again worsened his pulmonary hypertension, which was again
responsive to inhaled nitric oxide and resolved upon completion
of the chemotherapy cycle. In between rounds of therapy, he
remained stable without clinical or echocardiographic signs of
pulmonary hypertension.
Patient 4 was a 14-month-old female with haematuria and a
right flank mass eventually diagnosed with stage IV high-risk
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neuroblastoma. Before chemotherapy, she had an echocardio-
gram that showed normal biventricular function and no signs of
elevated right ventricular pressure. She received induction with
carboplatin and etoposide and subsequently received cyclopho-
sphamide, topotecan, cisplatin, etoposide, doxorubicin, and vin-
cristine. Owing to persistence of disease, she then underwent an
autologous stem cell transplant, local control with surgery, and
photon beam radiation to her pelvis. After 9 months of adjuvant
chemotherapy with dinutuximab and isotretinoin, she was
admitted to the ICU with new desaturation, hypotension, and
respiratory distress. Her physical examination revealed hepato-
megaly and laboratory studies showed an elevated B-type
natriuretic peptide of 3378 pg/ml. Her blood counts were incon-
sistent with thrombotic microangiopathy. Despite a normal
echocardiogram 3 weeks before admission, a repeat study showed
increased right atrial size though normal velocity to tricuspid
regurgitation jet. CT scan of her chest showed no pulmonary
embolus and scattered ground glass opacities. She was intubated,
started on nitric oxide and epinephrine, with improved perfusion
and oxygenation. With diuresis and initiation of methylpredni-
sone for possible interstitial pneumonitis, she had improved
ventilation, oxygenation, and systemic perfusion. During attempts
to wean off steroids and nitric oxide, she had worsening clinical,
laboratory, and echocardiographic signs of pulmonary hyper-
tension prompting evaluation by cardiac catheterisation. At that
time she was found to have mean pulmonary artery pressure of
30mmHg, left ventricular end diastolic pressure of 9mmHg, and
indexed pulmonary vascular resistance of 5.6Woods units ×m2,
which improved with inhaled nitric oxide testing to mean pul-
monary artery pressure of 21mmHg, no change in left ventricular
end diastolic pressure, and indexed pulmonary vascular resistance
of 3.1Woods units ×m2. With addition of amlodipine and con-
tinued sildenafil, she was weaned off inhaled nitric oxide. She
underwent subsequent rounds of radiation and chemotherapy
with interleukin-2 and dinutuximab without worsening of
pulmonary hypertension. She has had no further issues and is
currently weaning off sildenafil.
Discussion
This report is the first to outline the severity of pulmonary
hypertension symptoms in children undergoing treatment
for cancer. All four of these patients presented with cardiovascular
compromise requiring intensive care support and prompt initiation
of pulmonary hypertension-directed therapy. Despite the small
cohort of children reported, important features regarding their
malignancies, therapeutic regimens, as well as treatment course
may prove applicable to any child undergoing chemotherapy.
Why these children developed pulmonary hypertension is
unclear. Interestingly, all four had solid tumors with three of them
of neuroectodermal origin. However, the fact that all four chil-
dren had normal echocardiograms free of pulmonary hyperten-
sion findings, before initiation of treatment, makes the
chemotherapeutic drugs more likely the cause of their pulmonary
hypertension rather than underlying disease. Previous studies
have implicated several chemotherapeutic agents in association
with pulmonary hypertension, including alkylating agents, anti-
metabolites, kinase inhibitors, and cytotoxic antibiotics agents.7,8
Alkylating agents, in particular cyclophosphamide, have been
most often implicated in previous reports and were used in
greater than half of the chemotherapy-induced cases of pul-
monary hypertension in a report from the French Pulmonary
Hypertension Network.7 Cyclophosphamide and other alkylating
agents were part of the treatment protocols for each of the
patients reported in this cohort. However, the vast majority of
Table 1. Important patient features including underlying risk factors and pulmonary hypertension treatment regimens.
Disease
Chemotherapeutic
classes Radiation
Underlying PH risk
factors Acute PH medications
Outpatient
PH therapy
Patient 1 Metastatic embryonal
rhabdomyosarcoma
Alkylating agents
Anthracyclines
Vinca alkaloids
Topoisomerase II
inhibitors
Nasopharyngeal directed Bronchopulmonary
dysplasia and
prematurity
Inotropes, inhaled nitric
oxide, steroids
Sildenafil,
steroids
Patient 2 Pineal blastoma Alkylating agents
Antimetabolites
Topoisomerase II
inhibitor
Vinca alkaloids
None Hepatic veno-occlusive
disease
Inotropes, inhaled nitric
oxide, steroids
None
Patient 3 Metastatic
neuroblastoma
Alkylating agents
Anthracyclines
Topoisomerase I
inhibitor
Topoisomerase II
inhibitor
Vinca alkaloids
Infra-diaphragmatic
(minimal exposure to
lungs)
None Inotropes, diuretics,
steroids, inhaled nitric
oxide
Sildenafil,
steroids
Patient 4 Metastatic
neuroblastoma
Alkylating agents
Anthracyclines
Metal salts
Topoisomerase I
inhibitors
Topoisomerase II
inhibitors
Vinca alkaloids
Pelvic none Inotropes, diuretics,
steroids, inhaled nitric
oxide
Sildenafil,
steroids
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children treated with alkylating drugs do not develop pulmonary
hypertension making the association less clear.
Notably, these patients had a normal echocardiogram without
signs of elevated right ventricular pressures for a median of
2 months before the initial diagnosis. Despite the severe initial
presentations requiring intensive care admissions, the severe
pulmonary hypertension symptoms were remarkably responsive
to a combination of halting current chemotherapeutic regimens
and initiation of inhaled nitric oxide, sildenafil, and prednisone.
Kinase inhibitors, in particular dasatinib, have described side
effects of pulmonary complications including rapid onset of
pulmonary hypertension with rapid resolution on discontinuation
of medications in adults.8,9 However, none of the children in this
cohort were exposed to dasatinib or other kinase inhibitors. Two
of the patients had medical history that may be associated with
the development of pulmonary hypertension. Although she was
clinically without signs of pulmonary dysfunction before her
cancer diagnosis, Patient 1 did have bronchopulmonary dysplasia,
a known risk factor for the development of pulmonary hyper-
tension.10 This may indicate that chemotherapeutic agents were
an additional trigger for this patient. Also, of note, Patient 2 was
also found to have hepatic veno-occlusive disease shortly before
pulmonary hypertension symptoms and diagnosis along with
radiographic evidence with findings consistent with pulmonary
veno-occlusive disease. Though it seems possible that pulmonary
veno-occlusive disease caused the pulmonary hypertension, the
marked symptomatic improvement with pulmonary vasodilators
is inconsistent with a post-capillary pulmonary hypertension
disease aetiology. Definitive diagnosis by pathology was not
pursued given overall pulmonary hypertension improvement.
Paediatric oncologic patients have been associated with throm-
botic microangiopathy after haematopoietic stem cell transplant
with pulmonary hypertension, though in these patients the dis-
ease process was unresponsive to pulmonary vasodilators and
heralded rapid clinical deterioration.11
Glucocorticoids were used as part of the pulmonary hyperten-
sion treatment protocols andwere linked to the rapid improvement.
The association between inflammation and pulmonary hyper-
tension has been established in human autopsy studies, animal
models of pulmonary hypertension, and referenced by numerous
studies.12 In fact, pulmonary hypertension in animalmodels caused
by an alkylating agent, monocrotaline, has both identified inflam-
mation as a pathway for development of pulmonary hypertension
and demonstrated therapeutic benefit through treatment with
glucocorticoids.13,14 Though not commonly used, the modulatory
effect and clinical improvement in pulmonary hypertension has
previously been reported.15,16 After considering the effects
on oncologic therapeutic regimens, a short course of glucocorti-
coids may be an important auxiliary option for these children.
This single-centre retrospective description of cancer and
pulmonary hypertension is limited by a small patient cohort and
is unable to isolate an incidence of the disease. However, these
cases highlight an important association previously unreported in
the paediatric literature, despite significant attention to pulmon-
ary complications.6 A singular pathophysiological relationship
will unlikely be identified given the heterogeneous patient medical
history, tumour types, and treatment courses of patients who
develop this complication. However, this report indicates that
children treated for solid tumours who develop respiratory dis-
tress, evidence of right heart failure, or cardiogenic shock must be
evaluated for pulmonary hypertension. After ruling out pul-
monary embolism, echocardiography is able to provide rapid,
non-invasive screening for pulmonary hypertension to help guide
further clinical decisions. Prompt diagnosis of pulmonary
hypertension and treatment with pulmonary vasodilators and
steroids may allow rapid resolution of symptoms allowing che-
motherapy and radiation regimens to continue (Table 1).
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